Imatinib (Glivec, formerly STI571) was the first available BCR/ABL targeted therapy and produced complete cytogenetic responses in 70–85% of patients with CML in early CP [5]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.